Raphael Clynes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
Abstract: Provided herein are dimeric IL-7-Fc fusion proteins that include Fc domains and one or more IL-7s. Also provided herein are variant IL-7s with modifications to reduce heterogeneity and/or reduced affinity/potency. Such variant IL-7s are useful, for example, in the subject dimeric IL-7-Fc fusion proteins. The dimeric IL-7-Fc fusion proteins can be used for applications where increased IL-7 activity is useful, for example, for increasing the proliferation of lymphocyte populations in mounting an anti-tumor response in a subject in need thereof.
May 15, 2020
March 11, 2021
Matthew Bernett, John Desjarlais, Suzanne Schubbert, Christine Bonzon, Rajat Varma, Raphael Clynes
Abstract: The presently disclosed subject matter relates to biomarkers allowing for improved diagnosis and prognosis of alopecia areata as well as effective treatments for the disease, including methods that incorporate biomarkers capable of identifying patient sub-populations that will respond to such treatments and methods that incorporate biomarkers capable of tracking the progress of such treatments.
Abstract: The presently disclosed subject matter relates, in certain embodiments, to compositions and methods for the inhibition of the JAK-STAT pathway in order to induce hair growth. In certain embodiments, the presently disclosed subject matter relates to topical treatments with small molecule inhibitors of the JAK-STAT pathway to induce hair growth.
Abstract: The invention provides for methods for controlling hair growth by administering a HLDGC modulating compound to a subject. The invention further provides for a method for screening compounds that bind to and modulate polypeptides encoded by HLDGC genes. The invention also provides methods of detecting the presence of or a predisposition to a hair-loss disorder in a human subject as well as methods of treating such disorders.
Abstract: The invention is based in part on the finding that suppressing regulatory T cell function is needed in order to convert passive immunity into active antigen-specific immunity. Generally, the methods of the invention comprise at least the combination of: (1) increasing the amount of immune complexes in the subject, wherein the immune complex comprises a target antigen and a immunoglobulin molecule comprising (i) a variable region specific to the target antigen and (ii) a Fc receptor binding region; and (2) inhibiting regulatory T cell function or decreasing/depleting the regulatory T cell population in the subject.
February 17, 2009
August 27, 2009
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK